[The use of bemitil in patients with progressive muscular dystrophies].
Bemithyl treatment was carried out in 22 patients with neuromuscular diseases (progressive myodystrophy). The actoprotector bemithyl inhibited in these patients the processes of lipid peroxidation, activation of neoglucogenesis favours improvement of interorganic exchange of metabolites. Bemithyl is recommended in patients with progressive myodystrophy along with drugs normalizing the protein, energy and electrolyte metabolism.
Lobzin
V S
VS
Saĭkova
L A
LA
Chukhlovina
M L
ML
Pustozerov
V G
VG
D000293:Adolescent; D000328:Adult; D000975:Antioxidants / Q000627:therapeutic use*; D001562:Benzimidazoles / Q000627:therapeutic use*; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D015227:Lipid Peroxidation / Q000187:drug effects; D008297:Male; D008875:Middle Aged; D009136:Muscular Dystrophies / Q000097:blood / Q000188:drug therapy*; D009223:Myotonic Dystrophy / Q000097:blood / Q000188:drug therapy; D013577:Syndrome
D000975:Antioxidants; D001562:Benzimidazoles; C049825:bemethyl
Primenenie bemitila u bol'nykh progressiruiushchimi myshechnymi distrofiiami.